Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00375245
Other study ID # 14435B
Secondary ID
Status Completed
Phase Phase 1
First received September 11, 2006
Last updated January 16, 2014
Start date September 2006
Est. completion date May 2012

Study information

Verified date January 2014
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date May 2012
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

- Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion of the trial only.

- At least 4 weeks since prior chemotherapy or radiation therapy

- Aged 18 years or older

- ECOG performance status 0-2

- Life expectancy of greater than 3 months.

- Normal organ and marrow function:

- No transfusions of packed red blood cells within 1 week of starting treatment

- Leukocytes greater or equal to 3,000/µL

** White blood cell (WBC) greater or equal to 1,500/µL for patients with hematologic malignancies

- Absolute neutrophil count (ANC) greater or equal to 1,500/µL

** ANC greater or equal to 1,000/µL for patients with hematologic malignancies

- Platelets (PLT) greater or equal to 100,000/µL

** PLT greater or equal to 50,000/µL for patients with hematologic malignancies

- Total bilirubin within normal institutional limits

- AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper limit of normal

- Serum triglycerides less than or equal to 500 mg/dl

- Creatinine within normal institutional limits OR creatinine clearance greater or equal to 60 mL/min for patients with creatinine levels above institutional normal

- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

- May not be receiving any other investigational agents.

- Uncontrolled brain metastases or malignancy. Cannot be receiving enzyme-inducing anticonvulsants.

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin

- Gastrointestinal malabsorption syndromes, partial small bowel obstruction, or any illness that would interfere with the ability to absorb oral medications.

- Uncontrolled intercurrent illness

- Severe immunodeficient states (as judged by the treating physician)

- Pregnant women are excluded from this study; breastfeeding should be discontinued.

- HIV-positive patients receiving combination antiretroviral therapy are excluded.

- Concurrent use of ketoconazole, cyclosporine, tacrolimus, diltiazem, and rifampin with rapamycin is not permissible. The concurrent use of calcium channel blockers, terfenadine, astemizole, cisapride, propafenone, cyclosporine, midazolam, triazolam, quinidine, or theophylline with grapefruit juice is not permissible.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rapamycin (sirolimus)
Weekly oral doses, dose is assigned at the time of study entry
Other:
Grapefruit Juice
Daily oral doses starting during the second week on study.

Locations

Country Name City State
United States University of Chicago Hospitals Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetic interaction 4 weeks No
See also
  Status Clinical Trial Phase
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT04458259 - Study of PF-07265807 in Participants With Metastatic Solid Tumors. Phase 1
Completed NCT01218542 - Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc N/A
Not yet recruiting NCT03175146 - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely N/A
Active, not recruiting NCT02395224 - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT01960829 - Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study Phase 2
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00207116 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1